Silo Pharma (SILO) announced that it has engaged Veloxity Labs for bioanalysis supporting the ongoing investigational new drug-enabling GLP-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder. Silo expects to begin the FDA IND process for SPC-15 in 2025. Upon approval of the IND, Silo will proceed to a first-in-human Phase 1 clinical trial.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma enters agreement with Frontage Laboratories for SPC-15 study
- Silo Pharma announces results for its preclinical study on SP-26
- Silo Pharma files patent application with USPTO for SPC-14
- Silo Pharma files to sell 4.72M shares of common stock, warrants
- Silo Pharma announces first dosing in IND-enabling study for SPC-15